Medications proven to prevent breast cancers in women at high risk of the disease have been approved for use in the United States since 1998, but only a surprisingly small percentage of women actually choose to use these drugs. A new Susan G. Komen Perscpectives article – co-written by CNiC staff – explores this issue in detail – discussing risks and benefits of chemoprevention, who is likely to benefit the most from such medications, and possible reasons why usage is so low.
Susan G. Komen for the Cure
Medications to Prevent Breast Cancer: Missed Opportunities?